Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
First Tracks Biotherapeutics does not have enough data to calculate 3-Year RORE %.
First Tracks Biotherapeutics (HAM:B43) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
First Tracks Biotherapeutics 3-Year RORE % Related Terms
First Tracks Biotherapeutics 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics 3-Year RORE % Chart
First Tracks Biotherapeutics Annual Data
Trend
Dec23
Dec24
3-Year RORE %
0.00
0.00
First Tracks Biotherapeutics Semi-Annual Data
Dec23
Dec24
3-Year RORE %
0.00
0.00
HAM:B43 vs ALT, RGNX, MDXG: 3-Year RORE % Comparison
For the Biotechnology subindustry, First Tracks Biotherapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
First Tracks Biotherapeutics 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where First Tracks Biotherapeutics's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2024 and 3-year before.
First Tracks Biotherapeutics (HAM:B43) has a 3-Year RORE % of 0.00 as of Dec. 2024. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on First Tracks Biotherapeutics and its competitors. According to the industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 1291 companies in the Biotechnology industry.
Is First Tracks Biotherapeutics' 3-Year RORE % too high?
First Tracks Biotherapeutics' current 3-Year RORE % is 0.00. Based on the distribution chart, First Tracks Biotherapeutics ranks #999999 out of 1291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' 3-Year RORE % compare to ALT and RGNX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 1291 companies for 3-Year RORE %. This places First Tracks Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current 3-Year RORE % is 0.00 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score
Get the complete analysis for HAM:B43
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:B43 has been successfully added to your 